Do Exophytic and Endophytic Patterns in Borderline Ovarian Tumors Have Different Prognostic Implications? A Large Multicentric Experience

Borderline ovarian tumor (BOT) accounts for 15–20% of all epithelial ovarian tumors. Concerns have arisen about the clinical and prognostic implications of BOT with exophytic growth patterns. We retrospectively reviewed all cases of BOT patients surgically treated from 2015 to 2020. Patients were divided into an endophytic pattern (with intracystic tumor growth and intact ovarian capsule) and an exophytic pattern (with tumor growth outside the ovarian capsule) group. Among the 254 patients recruited, 229 met the inclusion criteria, and of these, 169 (73.8%) belonged to the endophytic group. The endophytic group showed more commonly an early FIGO stage than the exophytic group (100.0% vs. 66.7%, p < 0.001). Furthermore, tumor cells in peritoneal washing (20.0% vs. 0.6%, p < 0.001), elevated Ca125 levels (51.7% vs. 31.4%, p = 0.003), peritoneal implants (0 vs. 18.3%, p < 0.001), and invasive peritoneal implants (0 vs. 5%, p = 0.003) were more frequently observed in the exophytic group. The survival analysis showed 15 (6.6%) total recurrences, 9 (5.3%) in the endophytic and 6 (10.0%) patients in the exophytic group (p = 0.213). At multivariable analysis, age (p = 0.001), FIGO stage (p = 0.002), fertility-sparing surgery (p = 0.001), invasive implants (p = 0.042), and tumor spillage (p = 0.031) appeared significantly associated with recurrence. Endophytic and exophytic patterns in borderline ovarian tumors show superimposable recurrence rates and disease-free survival.

[1]  L. Horn,et al.  2020 WHO Classification of Female Genital Tumors , 2021, Geburtshilfe und Frauenheilkunde.

[2]  C. Genestie,et al.  Results After Conservative Surgery of Stage II/III Serous Borderline Ovarian Tumors , 2020, Annals of Surgical Oncology.

[3]  C. Genestie,et al.  Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers , 2020, Virchows Archiv.

[4]  L. Cope,et al.  Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma , 2019, The American journal of surgical pathology.

[5]  D. Timmerman,et al.  ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  G. Scambia,et al.  Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non‐invasive malignant serous ovarian tumors , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[7]  P. Sadłecki,et al.  KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[8]  P. Sadłecki,et al.  Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[9]  Steffen Hauptmann,et al.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria , 2016, Virchows Archiv.

[10]  D. Jurkovic,et al.  Ultrasound diagnosis of serous surface papillary borderline ovarian tumor: A case series with a review of the literature , 2015, Journal of clinical ultrasound : JCU.

[11]  M. Plebani,et al.  Borderline Ovarian Tumors and Diagnostic Dilemma of Intraoperative Diagnosis: Could Preoperative He4 Assay and ROMA Score Assessment Increase the Frozen Section Accuracy? A Multicenter Case-Control Study , 2014, BioMed research international.

[12]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Tumors of Low Malignant Potential (Borderline Ovarian Tumors) , 2014, International Journal of Gynecologic Cancer.

[13]  W. Kuehn,et al.  Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. , 2014, Anticancer research.

[14]  Jaime Prat,et al.  2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. , 2014, Gynecologic oncology.

[15]  M. Uetani,et al.  The MRI findings in a case of ovarian mucinous borderline tumor mimicking a serous surface borderline tumor , 2014, Japanese Journal of Radiology.

[16]  L. Cope,et al.  Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants , 2014, The Journal of pathology.

[17]  M. lenhard,et al.  KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants , 2013, BMC Cancer.

[18]  Young Tae Kim,et al.  Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. , 2013, American journal of obstetrics and gynecology.

[19]  M. Zikan,et al.  Diagnosis, treatment, and follow-up of borderline ovarian tumors. , 2012, The oncologist.

[20]  E. Darai,et al.  Management and prognosis of endometrioid borderline tumors of the ovary. , 2012, Surgical oncology.

[21]  E. Darai,et al.  Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. , 2012, The Lancet. Oncology.

[22]  R. Barakat,et al.  Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. , 2010, Gynecologic oncology.

[23]  I. Shih Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter? , 2010, Gynecologic oncology.

[24]  A. Malpica,et al.  Ovarian Intestinal Type Mucinous Borderline Tumors: Are We Ready for a Nomenclature Change? , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  L. Holmberg,et al.  Borderline ovarian tumors in Sweden 1960–2005: Trends in incidence and age at diagnosis compared to ovarian cancer , 2008, International journal of cancer.

[26]  D. Timmerman,et al.  Imaging in gynecological disease , 2007, Ultrasound in Obstetrics and Gynecology.

[27]  A. Ayhan,et al.  Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? , 2007, Acta obstetricia et gynecologica Scandinavica.

[28]  W. R. Hart Borderline epithelial tumors of the ovary , 2005, Modern Pathology.

[29]  C. Gilks,et al.  Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. , 2004, Human pathology.

[30]  R. Kurman,et al.  Borderline ovarian tumors: key points and workshop summary. , 2004, Human pathology.

[31]  D. Gershenson Ovarian Tumors of Low Malignant Potential , 2003 .

[32]  R. Kurman,et al.  Pathology of ovarian carcinoma. , 2003, Hematology/oncology clinics of North America.

[33]  R. Kurman,et al.  Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the Ovary: A Clinicopathologic Analysis of 135 Cases , 2003, The American journal of surgical pathology.

[34]  C. Haie-meder,et al.  Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  J. Gu,et al.  Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. , 2001, Journal of the National Cancer Institute.

[36]  C. Mangioni,et al.  Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Scully,et al.  Mucinous Tumors of the Ovary: A Clinicopathologic Study of 196 Borderline Tumors (of Intestinal Type) and Carcinomas, Including an Evaluation of 11 Cases With `Pseudomyxoma Peritonei' , 2000, The American journal of surgical pathology.

[38]  T. Bourne,et al.  Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group , 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[39]  R. Kurman,et al.  Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. , 2000, Human pathology.

[40]  R. Berkowitz,et al.  Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. , 1998, Cancer research.

[41]  W. R. Hart,et al.  Ovarian Serous Tumors of Low Malignant Potential (Serous Borderline Tumors) The Relationship of Exophytic Surface Tumor to Peritoneal “Implants” , 1992, The American journal of surgical pathology.

[42]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[43]  Kathleen R. Cho,et al.  Surface Epithelial Tumors of the Ovary , 2011 .

[44]  P. Morice,et al.  Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. , 2001, Fertility and sterility.

[45]  J. Berg,et al.  Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. , 1982, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.